Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABT Abbott Laboratories	$132.35 +0.1%	$132.07	$99.71 ▼ $141.23	$230.37B	0.73	6.09 million shs	4.95 million shs
AZN AstraZeneca	$70.76 -0.3%	$70.26	$61.24 ▼ $87.68	$219.45B	0.38	5.18 million shs	3.37 million shs
NVS Novartis	$115.97 -0.4%	$112.90	$96.06 ▼ $120.92	$244.96B	0.59	1.57 million shs	1.00 million shs
PFE Pfizer	$23.88 -0.5%	$23.22	$20.92 ▼ $31.54	$135.77B	0.57	41.08 million shs	37.06 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABT Abbott Laboratories	0.00%	-2.92%	-2.09%	+4.89%	+27.27%
AZN AstraZeneca	0.00%	-5.65%	+1.20%	-5.57%	-9.77%
NVS Novartis	0.00%	-3.91%	+3.27%	+3.45%	+10.51%
PFE Pfizer	0.00%	-3.92%	+1.55%	-8.89%	-12.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABT Abbott Laboratories	4.9291 of 5 stars	2.4	5.0	4.2	4.5	2.9	2.5	2.5
AZN AstraZeneca	2.8852 of 5 stars	2.6	5.0	1.7	0.0	2.7	0.0	1.3
NVS Novartis	1.8546 of 5 stars	1.0	4.0	2.5	0.0	2.8	0.0	1.9
PFE Pfizer	4.8838 of 5 stars	2.3	4.0	4.2	4.3	2.9	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABT Abbott Laboratories	2.76	Moderate Buy	$142.61	7.75% Upside
AZN AstraZeneca	3.13	Buy	$85.00	20.12% Upside
NVS Novartis	2.00	Hold	$123.38	6.38% Upside
PFE Pfizer	2.53	Moderate Buy	$29.17	22.16% Upside

Current Analyst Ratings Breakdown

Latest ABT, PFE, AZN, and NVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	ABT Abbott Laboratories	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	ABT Abbott Laboratories	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$143.00
4/30/2025	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$24.00 ➝ $25.00
4/22/2025	PFE Pfizer	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Neutral	$24.00
4/17/2025	ABT Abbott Laboratories	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$133.00 ➝ $145.00
4/17/2025	ABT Abbott Laboratories	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$132.00 ➝ $142.00
4/17/2025	ABT Abbott Laboratories	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$140.00 ➝ $145.00
4/17/2025	ABT Abbott Laboratories	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$117.00 ➝ $127.00
4/17/2025	ABT Abbott Laboratories	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$136.00 ➝ $147.00
4/17/2025	ABT Abbott Laboratories	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$158.00 ➝ $159.00
4/17/2025	ABT Abbott Laboratories	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$135.00 ➝ $145.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABT Abbott Laboratories	$42.34B	5.44	$6.58 per share	20.11	$27.62 per share	4.79
AZN AstraZeneca	$54.07B	4.06	$6.30 per share	11.24	$13.18 per share	5.37
NVS Novartis	$50.32B	4.87	$10.70 per share	10.84	$21.59 per share	5.37
PFE Pfizer	$62.46B	2.17	$4.36 per share	5.47	$15.62 per share	1.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABT Abbott Laboratories	$13.40B	$7.71	17.17	23.10	2.51	31.89%	19.01%	10.82%	7/17/2025 (Estimated)
AZN AstraZeneca	$7.04B	$2.49	28.42	14.15	1.30	14.14%	33.14%	12.83%	7/24/2025 (Estimated)
NVS Novartis	$11.94B	$6.40	18.12	13.16	1.67	24.70%	39.44%	16.43%	7/17/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	17.30	7.88	0.87	12.62%	20.33%	8.53%	7/29/2025 (Estimated)

Latest ABT, PFE, AZN, and NVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/17/2025	Q2 2025	ABT Abbott Laboratories	$1.25	N/A	N/A	N/A	$11.01 billion	N/A
7/17/2025	Q2 2025	NVS Novartis	$2.37	N/A	N/A	N/A	$13.94 billion	N/A
4/29/2025	Q1 2025	AZN AstraZeneca	$1.10	$1.24	+$0.14	$0.93	$13.71 billion	$13.59 billion
4/29/2025	Q1 2025	NVS Novartis	$2.12	$2.28	+$0.16	$1.83	$12.92 billion	$13.23 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/16/2025	Q1 2025	ABT Abbott Laboratories	$1.07	$1.09	+$0.02	$0.76	$10.38 billion	$10.36 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABT Abbott Laboratories	$2.36	1.78%	N/A	30.61%	54 Years
AZN AstraZeneca	$2.06	2.91%	N/A	82.73%	N/A
NVS Novartis	$2.60	2.24%	N/A	40.63%	N/A
PFE Pfizer	$1.72	7.20%	N/A	124.64%	16 Years

Latest ABT, PFE, AZN, and NVS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/13/2025	ABT Abbott Laboratories	quarterly	$0.59	1.73%	7/15/2025	7/15/2025	8/15/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABT Abbott Laboratories	0.26	1.78	1.27
AZN AstraZeneca	0.65	0.90	0.70
NVS Novartis	0.56	0.79	0.61
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABT Abbott Laboratories	75.18%
AZN AstraZeneca	20.35%
NVS Novartis	13.12%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ABT Abbott Laboratories	0.46%
AZN AstraZeneca	N/A
NVS Novartis	0.01%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABT Abbott Laboratories	114,000	1.74 billion	1.73 billion	Optionable
AZN AstraZeneca	94,300	3.10 billion	N/A	Optionable
NVS Novartis	75,883	2.11 billion	2.11 billion	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

ABT, PFE, AZN, and NVS Headlines

Recent News About These Companies

Pfizer Inc. (NYSE:PFE) Shares Sold by Means Investment CO. Inc.

June 20 at 5:48 AM | marketbeat.com

Pfizer: An Offensive Play For A Bear Market

June 20 at 5:20 AM | seekingalpha.com

Envestnet Portfolio Solutions Inc. Trims Stake in Pfizer Inc. (NYSE:PFE)

June 20 at 5:03 AM | marketbeat.com

Pfizer: An Offensive Play For A Bear Market

June 20 at 5:01 AM | seekingalpha.com

Pfizer Inc. (NYSE:PFE) Shares Bought by Johnson Investment Counsel Inc.

June 20 at 4:42 AM | marketbeat.com

Wealth Enhancement Advisory Services LLC Has $66.04 Million Holdings in Pfizer Inc. (NYSE:PFE)

June 20 at 3:47 AM | marketbeat.com

Is It Time to Invest in Pfizer? Exploring its 7% Dividend Yield and Growth Potential

June 19 at 6:55 PM | 247wallst.com

Is It Time to Invest in Pfizer? Exploring its 7% Dividend Yield and Growth Potential

June 19 at 6:44 PM | 247wallst.com

Travis Kelce Is Getting Destroyed After New Report Reveals Insane Amount Of Money He Made From Pfizer

June 19 at 3:03 PM | msn.com

Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?

June 19 at 10:51 AM | zacks.com

ORG Wealth Partners LLC Acquires 57,112 Shares of Pfizer Inc. (NYSE:PFE)

June 19 at 7:23 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Stock Holdings Lifted by Steel Grove Capital Advisors LLC

June 19 at 5:32 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Sold by Clarius Group LLC

June 19 at 4:49 AM | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Sagimet Biosciences, Inc. Class A (SGMT)

June 19 at 12:00 AM | theglobeandmail.com

RFK Jr weighs review of vaccines citing aluminum use, Bloomberg News reports

June 18 at 1:05 PM | reuters.com

RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury

June 18 at 1:01 PM | cnbc.com

3 High-Yield Dividend Stocks Increasing Payouts For Decades

June 18 at 9:42 AM | 247wallst.com

50% Off - 2 Dividend Gems With Huge Income And Growth Potential

June 18 at 8:15 AM | seekingalpha.com

Community Bank N.A. Grows Position in Pfizer Inc. (NYSE:PFE)

June 18 at 7:18 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Stake Raised by State of Alaska Department of Revenue

June 18 at 7:00 AM | marketbeat.com

Kingswood Wealth Advisors LLC Has $5.84 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

June 18 at 6:29 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Pfizer's 7.5% Dividend: Income Haven or House of Cards?
By Jeffrey Neal Johnson | May 23, 2025
View Pfizer's 7.5% Dividend: Income Haven or House of Cards?

ABT, PFE, AZN, and NVS Company Descriptions

Abbott Laboratories NYSE:ABT

$132.35 +0.07 (+0.05%)

Closing price 06/18/2025 03:59 PM Eastern

Extended Trading

$132.12 -0.23 (-0.17%)

As of 04:50 AM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

AstraZeneca NASDAQ:AZN

$70.76 -0.21 (-0.30%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$71.44 +0.68 (+0.96%)

As of 05:51 AM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Novartis NYSE:NVS

$115.97 -0.44 (-0.38%)

Closing price 06/18/2025 03:59 PM Eastern

Extended Trading

$116.85 +0.88 (+0.76%)

As of 05:00 AM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Pfizer NYSE:PFE

$23.88 -0.13 (-0.52%)

Closing price 06/18/2025 03:59 PM Eastern

Extended Trading

$23.90 +0.02 (+0.10%)

As of 05:54 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time